Institution
International Agency for Research on Cancer
Government•Lyon, France•
About: International Agency for Research on Cancer is a government organization based out in Lyon, France. It is known for research contribution in the topics: Population & Cancer. The organization has 2989 authors who have published 9010 publications receiving 929752 citations. The organization is also known as: IARC.
Topics: Population, Cancer, Breast cancer, Risk factor, European Prospective Investigation into Cancer and Nutrition
Papers published on a yearly basis
Papers
More filters
Alexandria University1, American University of Beirut2, Tehran University of Medical Sciences3, University of the West Indies4, Centers for Disease Control and Prevention5, University of Kinshasa6, Wageningen University and Research Centre7, Cancer Research UK8, University of Oxford9, University of Pennsylvania10, University of Otago11, Newcastle University12, Lithuanian University of Health Sciences13, Medical Research Council14, All India Institute of Medical Sciences15, National Institutes of Health16, Mahidol University17, South African Medical Research Council18, RMIT University19, Deakin University20, Monash University21, World Health Organization22, International Agency for Research on Cancer23
1,911 citations
Ludwig Institute for Cancer Research1, University of Copenhagen2, University of Helsinki3, National Institute for Health and Welfare4, International Agency for Research on Cancer5, Norwegian University of Science and Technology6, Cayetano Heredia University7, Medical University of Warsaw8, Lund University9, Karolinska Institutet10, Boston Children's Hospital11, Emory University12, Indiana University – Purdue University Indianapolis13, Georgia Regents University14, University of Washington15, Johns Hopkins University16, Duke University17, Merck & Co.18
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Abstract: BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. METHODS: In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group who had no virologic evidence of infection with HPV-16 or HPV-18 through 1 month after the third dose (month 7). The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18. RESULTS: Subjects were followed for an average of 3 years after receiving the first dose of vaccine or placebo. Vaccine efficacy for the prevention of the primary composite end point was 98% (95.89% confidence interval [CI], 86 to 100) in the per-protocol susceptible population and 44% (95% CI, 26 to 58) in an intention-to-treat population of all women who had undergone randomization (those with or without previous infection). The estimated vaccine efficacy against all high-grade cervical lesions, regardless of causal HPV type, in this intention-to-treat population was 17% (95% CI, 1 to 31). CONCLUSIONS: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group.
1,904 citations
TL;DR: The global scale-up of HPV vaccination and HPV-based screening—including self-sampling—has potential to make cervical cancer a rare disease in the decades to come, and could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem.
1,867 citations
TL;DR: The International Agency for Research on Cancer convened a workshop on the relationship between body fatness and cancer, from which an IARC handbook on the topic will appear.
Abstract: The International Agency for Research on Cancer convened a workshop on the relationship between body fatness and cancer, from which an IARC handbook on the topic will appear. An executive summary of the evidence is presented.
1,858 citations
Aalborg University1, Utrecht University2, University of Oxford3, National and Kapodistrian University of Athens4, French Institute of Health and Medical Research5, German Cancer Research Center6, Harvard University7, Imperial College London8, University of Turin9, University of Naples Federico II10, Umeå University11, Lund University12, University of Tromsø13, University of Cambridge14, International Agency for Research on Cancer15
TL;DR: It is suggested that both general adiposity and abdominal adiposity are associated with the risk of death and support the use of waist circumference or waist-to-hip ratio in addition to BMI in assessing therisk of death.
Abstract: Background Previous studies have relied predominantly on the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) to assess the association of adiposity with the risk of death, but few have examined whether the distribution of body fat contributes to the prediction of death. Methods We examined the association of BMI, waist circumference, and waist-to-hip ratio with the risk of death among 359,387 participants from nine countries in the European Prospective Investigation into Cancer and Nutrition (EPIC). We used a Cox regression analysis, with age as the time variable, and stratified the models according to study center and age at recruitment, with further adjustment for educational level, smoking status, alcohol consumption, physical activity, and height. Results During a mean follow-up of 9.7 years, 14,723 participants died. The lowest risks of death related to BMI were observed at a BMI of 25.3 for men and 24.3 for women. After adjustment for BMI, waist circumfer...
1,804 citations
Authors
Showing all 3012 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| David J. Hunter | 213 | 1836 | 207050 |
| Kay-Tee Khaw | 174 | 1389 | 138782 |
| Elio Riboli | 158 | 1136 | 110499 |
| Silvia Franceschi | 155 | 1340 | 112504 |
| Stephen J. Chanock | 154 | 1220 | 119390 |
| Paolo Boffetta | 148 | 1455 | 93876 |
| Timothy J. Key | 146 | 808 | 90810 |
| Hans-Olov Adami | 145 | 908 | 83473 |
| Joseph J.Y. Sung | 142 | 1240 | 92035 |
| Heiner Boeing | 140 | 1024 | 92580 |
| Anne Tjønneland | 139 | 1345 | 91556 |
| Kim Overvad | 139 | 1196 | 86018 |
| Sheila Bingham | 136 | 519 | 67332 |
| Pasi A. Jänne | 136 | 685 | 89488 |
| Peter Kraft | 135 | 821 | 82116 |